Location of Repository

Inhibition of HIV budding by a genetically selected cyclic peptide targeting the Gag?TSG101 interaction

By Ali Tavassoli, Quan Lu, Jongsik Gam, Hui Pans, Stephen J. Benkovic and Stanley N. Cohen

Abstract

The egress of HIV particles from virus-infected cells is accomplished by the recruitment of proteins that normally mediate host cell endocytic functions. This process requires interaction of the HIV Gag protein with the host protein TSG101 (tumor susceptibility gene 101). Here, we report the use of a bacterial reverse two-hybrid system to identify cyclic peptides that interfere with the Gag?TSG101 interaction and the finding that a five amino acid peptide discovered by this approach can disrupt the interaction and consequently inhibit HIV egress. The inhibiting molecule, which was selected from a cyclic peptide library containing 3.2 × 106 members, differs in primary sequence from the interacting sites of either TSG101 or Gag. Addition of cyclic peptide tagged with an HIV Tat sequence, which previously has been shown to enhance protein translocation across plasma membranes, to cultured human cells inhibited the production of virus-like particles (VLPs) by these cells (IC50 of 7 ?M), and this inhibition occurred in the absence of adverse affects on normal endocytic functions mediated by TSG101. A mutant Gag protein not dependent on TSG101 for release was unaffected by the cyclic peptide. Our findings, which suggest that interference with the TSG101?Gag interaction by cyclic peptides may be of practical use in the treatment of HIV infections, identify a specific cyclic peptide that reduces VLP release by this mechanism; they also demonstrate that the efficiency of interference with protein?protein interactions by cyclic peptides can be enhanced by tagging the peptides with translocation-promoting sequences. Collectively our results support the notion that small molecule therapeutics that inhibit specific interactions between viral and host proteins may have general applicability in antiviral therapy.<br/

Topics: QD, QH426, RM
Year: 2008
OAI identifier: oai:eprints.soton.ac.uk:158653
Provided by: e-Prints Soton

Suggested articles

Preview

Citations

  1. (2004). A systematic method for identifying small-molecule modulators of proteinprotein interactions, doi
  2. (2001). Conditional-replication, integration, excision, and retrieval plasmid-host systems for gene structure-function studies of bacteria, doi
  3. (1991). Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release, doi
  4. Fisher,R.J.,andBurke,T.R.,Jr.(2008)SARbyoxime-containingpeptide libraries: application to Tsg101 ligand optimization, doi
  5. (2007). Genetic therapies against HIV, doi
  6. (2005). Genetically selected cyclicpeptide inhibitors of AICAR transformylase homodimerization, doi
  7. (2004). HIV drug resistance, doi
  8. (2003). HIV Gag mimics the Tsg101-recruiting activity of the human Hrs protein, doi
  9. (2001). HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress,
  10. (2004). HIV-1 and the host cell: an intimate association, doi
  11. (2004). HIV-host interactions: vital to the virus and key to its inhibition, doi
  12. (2003). Hrs regulatesmultivesicularbodyformationviaESCRTrecruitmenttoendosomes, doi
  13. (1990). Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are effi-ciently processed and assembled into viruslike particles,
  14. (2000). Localization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging, doi
  15. Lu,Q.,Hope,L.W.,Brasch,M.,Reinhard,C.,andCohen,S.N.(2003) TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation, doi
  16. (2004). Mechanisms of enveloped virus release, Virus Res. doi
  17. (1995). p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease,
  18. (2008). Protected aminooxyprolines for expedited library synthesis: application to Tsg101-directed proline-oxime containing peptides, doi
  19. (2002). Receptor downregulation and multivesicular-body sorting, doi
  20. (2004). Retrovirus budding, doi
  21. (2003). Role of HIV-1 Gag domains in viral assembly, doi
  22. (2007). Split-intein mediated circular ligation used in the synthesis of cyclic peptide libraries doi
  23. (2001). Structuralrequirementsforthebiosynthesisofbackbonecyclicpeptide libraries, doi
  24. (2001). The HIV assembly machine, AIDS 15,S u p p l . doi
  25. (2003). Tsg101 control of human immunodeficiency virus type 1 Gag trafficking and release, doi
  26. (2001). Tsg101, a homologue of ubiquitinconjugating (E2) enzymes, doi
  27. (1996). Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells, doi
  28. (2002). Viral late domains, doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.